Biology-driven discovery

Precision Single-Domain Antibody Therapeutics for Immuno-Oncology and Complex Targets

AI-assisted biology-driven innovation with real-world impact. Advancing next-generation sdAb therapeutics through biology-aware discovery and data-driven antibody design.

Explore Pipeline Partner With Us

3Active programs

2Discovery platforms

IOPrimary therapeutic focus

MGX-101 single-domain antibody in structural complex with target antigen

About us

Designed around biology that matters.

mAbGenEx develops next-generation single-domain antibody therapeutics by combining AI with deep biological insight, beginning with disease biology, functional epitopes, and mechanisms most likely to translate into meaningful clinical outcomes.

Our proprietary platforms integrate computational design with experimental validation to generate sdAb candidates optimized for specificity, developability, manufacturability, and therapeutic potential, while enabling access to complex targets and improved tissue penetration.

Biology-first discovery

Starts with disease biology and functional epitopes before antibody design.

AI + Translational science

Combines computational intelligence with experimental validation to accelerate discovery.

Precision sdAb therapeutics

Designed for complex targets where specificity, tissue access, and developability matter.

Technology

Two complementary discovery and design engines.

PrecinAb™ and OptinAb™ each generate therapeutic-grade antibody candidates independently, while also complementing one another to enhance candidate quality. For challenging targets, this integrated flexibility enables stronger, more developable leads.

PrecinAb™

Precision Antibodies Redefined

Biology-aware antibody design

Identifies the right target, epitope, and antibody concepts using biological insight and computational design.

Epitope-first strategy
Functional biology prioritization
Precision candidate generation

OptinAb™

Optimized Antibodies

Experimental optimization platform

Converts promising antibody concepts into optimized therapeutic leads through advanced screening and engineering.

Natural repertoire-inspired libraries
Selectivity-focused screening
Affinity and developability optimization

Pipeline

Focused therapeutic programs across oncology, complex disease biology, and next-generation antivenom development.

MGX-101

sdAb

Solid Tumors

Target: CCR8 · Lead immuno-oncology program targeting TME/Treg biology.

Differentiation: First in Class / Novel MoA

DiscoveryValidationPreclinicalIND

MGX-102

sdAb

Anti-snake Venom

Targets: PLA2, Btx · Next-gen monoclonal antivenom, moving beyond polyclonal approaches.

Differentiation: Monoclonal sdAb Cocktail

DiscoveryValidationPreclinicalIND

MGX-103

sdAb

Solid Tumors

Target: Undisclosed

Differentiation: Monoclonal sdAb

DiscoveryValidationPreclinicalIND

Leadership & advisory

Suresh Chintalapati, PhD, MBA

Founder, CEO and Chairman

With 25+ years in molecular biology, immunology, and biotechnology, he is dedicated to translating cutting-edge science into globally impactful healthcare solutions.

Satyamurthy Kundharapu, PhD

Director of Research

With over 15 years of experience in structural biology, protein chemistry, and therapeutic antibody engineering, he is committed to translating scientific innovation into next-generation biologics.

Lakshmipathi Khandrika, PhD

Principal Scientist

With over 22 years of experience in molecular biology, cell biology, and oncology research, he is committed to translating scientific discoveries into impactful healthcare innovations.